A Phase 2 interventional study of Adriamycin and Cytoxan (AC) and ABI-007 in Breast Cancer, sponsored by Celgene. Completed at 27 sites in United States. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-11-25.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 108 studies testing Albumin-Bound Paclitaxel in Breast Neoplasms — 18 open to participants now, 22 under way, 2 of them phase 3. Albumin-Bound Paclitaxel · Breast Neoplasms.
Among the 108 studies testing Albumin-Bound Paclitaxel in Breast Neoplasms, this one is the 20th largest by enrollment, is one of 9 that started in 2006, is one of 67 in phase 2, and was the 13th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.
Browse Breast Neoplasms studies →18 of the 108 studies testing Albumin-Bound Paclitaxel in Breast Neoplasms are open now, in 10 countries. Recruiting first, the newest first:
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75 · Women only
Henan Cancer Hospital · Sites in China
Ages 18–70
University of Illinois at Chicago · Sites in United States
Ages 18+
Dana-Farber Cancer Institute · Sites in United States
Ages 18+
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–70 · Women only
By country, each count listing its studies:
Albumin-Bound Paclitaxel: first FDA approval 2005 (ABRAXANE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years to 70 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
108 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 79 · Phase 3 11 · Phase 4 4
First in 2001; this study’s year is marked. 9 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 197 is above the median of 72 across 10,903 interventional studies indexed under Breast Neoplasms.
Median enrollment 60 across the 108 interventional studies. Of the 66 that completed or were terminated, 41 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 108 have an industry lead sponsor. The 10 most frequent:
This study is registered under Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
44 studies in Breast Neoplasms by Bristol-Myers Squibb: 4 open now, 4 under way, 1 of them phase 3. Of 39 finished, 20 (51%) have results posted.
Among the 44 studies in Breast Neoplasms by Bristol-Myers Squibb, this one is the 8th largest by enrollment of the 40 interventional ones that give a count, is one of 6 that started in 2006, is one of 23 in phase 2, and was the 13th registered.
Bristol-Myers Squibb’s Breast Neoplasms studies by the year they started, since 2001.
3 of the studies testing Albumin-Bound Paclitaxel in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05420454Second Affiliated Hospital, School of Medicine, Zhejiang UniversityA Study for the Neoadjuvant Treatment of Breast Cancer | 2027-06-10 |
| NCT05420467Second Affiliated Hospital, School of Medicine, Zhejiang UniversityA Study for the Adjuvant Treatment of Breast Cancer | 2027-07-10 |
| NCT05287308Chinese Academy of Medical SciencesAdjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 108 studies testing Albumin-Bound Paclitaxel in Breast Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bristol-Myers Squibb’s 44 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study was to compare the safety of dose-dense ABI-007 (Abraxane) 260 mg/m\^2 or Taxol 175 mg/m\^2 given every 2 weeks following dose-dense Adriamycin plus Cytoxan (AC) chemotherapy. Bevacizumab was administered at 10 mg/kg every 2 weeks throughout chemotherapy, and then at 15 mg/kg every 3 weeks following chemotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A patient was eligible for inclusion in this study only if all of the following criteria were met:
Must have met 1 of the following criteria:
Patients with more than one sentinel node micrometastasis or 1 node with a micrometastasis > 2 mm and/or T3 disease must have undergone completion, standard axillary dissection. -Note: the following were not eligible-
T1b,c,N0M0 and ER or PR positive and grade 1 or 2 Tx tumors (regardless of nodal status) T4 disease [i.e., patients with fixed tumors, peau d'orange skin changes, skin ulcerations, or inflammatory changes
Laboratory values were to be as follows:
Exclusion Criteria:
A patient was not eligible for inclusion in this study if any of the following criteria applied:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adriamycin and Cytoxan plus Bevacizumab for four cycles (weeks 1-8); 260 mg/m\^2 ABI-007 (Abraxane) plus Bevacizumab for four cycles (weeks 9-16); Bevacizumab (weeks 17-46).
Drug: Adriamycin and Cytoxan (AC) · Drug: ABI-007 · Drug: Bevacizumab · Drug: pegfilgrastim
Adriamycin and Cytoxan plus Bevacizumab for four cycles (weeks 1-8); 175 mg/m\^2 Taxol plus Bevacizumab for four cycles (weeks 9-16); Bevacizumab (weeks 17-46).
Drug: Adriamycin and Cytoxan (AC) · Drug: Taxol · Drug: Bevacizumab · Drug: pegfilgrastim
Drug pages: Doxorubicin · Cyclophosphamide
Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide) make up the chemotherapy regimen known as AC. Adriamycin 60 mg/m\^2 intravenous, plus Cytoxan 600 mg/m\^2 intravenous on Day 1 of each of four 2-week cycles (weeks 1-8).
Also known as: doxorubicin, cyclophosphamide
260 mg/m\^2 IV on day 1 of each of four 2-week cycle, representing treatment cycles 5-8 (weeks 9-16)
Also known as: Abraxane
175 mg/m\^2 intravenously (IV) on day 1 of each of four 2-week cycle, representing treatment cycles 5-8 (weeks 9-16)
Also known as: paclitaxel
10 mg/kg on day 1 of each of eight 2-week cycles (weeks 9-16), then 15 mg/kg on day 1 of each of ten three-week cycles (weeks 17-46).
Also known as: Avastin®
6 mg subcutaneous (SC) on day 2 for each of the first four 2-week cycles (weeks 1-8). Pegfilgrastim 6 mg SC was administered on day 2 of cycles 6-8 (weeks 11-16) during taxane treatment only if necessary.
Also known as: Neulasta
Participants With Treatment-Emergent Toxicities With a Frequency >=20% at 3 Months Post Chemotherapy
Toxicities are summarized using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) terms. Participants with treatment-emergent toxicities with a frequency of \>=20% in any treatment arm, and participants with at least one toxicity are reported. Taxane subsets (ABI-007 subset and Taxol subset treatment arms) summarize participants with treatment-emergent toxicities defined as any AEs that begin or worsen in severity grade after the start of taxane treatment (cycle 5, week 9) through 30 days after the last dose of taxane (week 20) and were ongoing 3 months after chemotherapy (month 7). Entire regiments (AC --\> ABI-007 and AC --\> Taxol treatment arms) summarize participants with treatment-emergent toxicities defined as any AEs that begin or worsen in severity grade after the start of chemotherapy (cycle 1, week 1) through 30 days after the last dose of chemotherapy (week 20) and were ongoing 3 months after chemotherapy (month 7).
Time frame: Month 7
Participants With Treatment-Emergent Toxicities With a Frequency >=20% at 6 Months Post Chemotherapy
Toxicities are summarized using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) terms. Participants with treatment-emergent toxicities with a frequency of \>=20% in any treatment arm, and participants with at least one toxicity are reported. Taxane subsets (ABI-007 subset and Taxol subset treatment arms) summarize participants with treatment-emergent toxicities defined as any AEs that begin or worsen in severity grade after the start of taxane treatment (cycle 5, week 9) through 30 days after the last dose of taxane (week 20) and were ongoing 6 months after chemotherapy (month 10). Entire regiments (AC --\> ABI-007 and AC --\> Taxol treatment arms) summarize participants with treatment-emergent toxicities defined as any AEs that begin or worsen in severity grade after the start of chemotherapy (cycle 1, week 1) through 30 days after the last dose of chemotherapy (week 20) and were ongoing 6 months after chemotherapy (month 10).
Time frame: Month 10
The Cumulative Dose of Taxane Delivered During Study
The cumulative dose of taxane (Taxol or ABI-007) taken during the study (cycles 4-8 which is approximately weeks 9-16).
Time frame: approximately week 9-16
Mean Taxane Dose Intensity Per Week
Cumulative taxane (ABI-007 or Taxol) dose divided by the number of weeks on taxane treatment.
Time frame: approximately week 9-16
Percent of Protocol Taxane Dose
Percent of the protocol-defined taxane (ABI-007 or Taxol) dose that was actually taken by study participants.
Time frame: approximately week 9-16
Summary of Participant Treatment Exposure, Dose Interruptions, Dose Reductions, and Dose Delays
Counts of participants who * completed the protocol-defined treatment cycles, * had a dose interruption * had a dose reduction * had a dose delay. A dose delay refers to the delay of all interventions in the cycle. Dose modifications are typically caused by clinically significant laboratory abnormalities and /or treatment emergent adverse events/toxicities. Use of pegfilgrastim is included in the summary.
Time frame: up to Week 46
Myelosuppression During Taxane Dosing Cycles
Myelosuppression represented by neutropenia (low absolute neutrophil counts (ANC)) with severity grades according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE). * Grade 1 = \<lower limit of normal (LLN)-1.5\*10\^9/L * Grade 2 = \<1.5 - 1.0\*10\^9/L * Grade 3 = \<1.0 - 0.5\*10\^9/L * Grade 4 = \<0.5\*10\^9/L Values are reported across all severity grades without assessment of relationship to taxane treatment, and also by relation to taxane treatment as reported by investigators.
Time frame: Weeks 9-16
Change From Baseline in Percent Left Ventricular Ejection Fraction (% LVEF) at the Final Evaluation
Decreased left ventricular ejection fraction (LVEF) is an indication of cardiotoxicity. Change from baseline measurements to the final evaluation are summarized.
Time frame: up to week 46
Summary of Participants' Most Severe Grade for Liver and Renal Function Laboratory Adverse Experiences During Study (All Treatment Cycles)
Summary of the most severe grades using the National Cancer Institute's Common Terminology Criteria for Adverse Events v3.0 (CTCAE) for the following liver and renal function tests. Grade 0 = within normal range for all measurements. Alkaline phosphatase, alanine aminotransferase (ALT), aspartate aminotransferase (AST): * Grade 1 = \> upper limit of normal (ULN) - 2.5\*ULN * Grade 2= \>2.5-5.0\*ULN * Grade 3= \>5.0-20.0\*ULN * Grade 4= \>20.0\*ULN Bilirubin: * Grade 1= \>ULN - 1.5\*ULN * Grade 3= \>3.0 - 10.0\*ULN Creatinine: - Grade 1= \>ULN - 1.5\*ULN
Time frame: Week 1 up to week 50
Multicenter study
| Milestone | AC --> ABI-007 | AC --> Taxol |
|---|---|---|
| Started | 98 | 99 |
| At least one dose of taxane | 93 | 93 |
| Completed | 61 | 61 |
| Not completed | 37 | 38 |
| Withdrew: Adverse event | 7 | 5 |
| Withdrew: Unacceptable toxicity | 20 | 18 |
| Withdrew: Physician decision | 1 | 1 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Withdrawal by subject | 7 | 11 |
| Withdrew: Non-compliance, pt moved, pt/inv agree | 2 | 2 |
The cumulative dose of taxane (Taxol or ABI-007) taken during the study (cycles 4-8 which is approximately weeks 9-16).
| mg/m^2 | AC --> ABI-007 | AC --> Taxol |
|---|---|---|
| The Cumulative Dose of Taxane Delivered During Study | 950.5 ± 199.86 | 660.8 ± 99.52 |
Cumulative taxane (ABI-007 or Taxol) dose divided by the number of weeks on taxane treatment.
| mg/m^2/week | AC --> ABI-007 | AC --> Taxol |
|---|---|---|
| Mean Taxane Dose Intensity Per Week | 118.82 ± 24.983 | 82.60 ± 12.440 |
Toxicities are summarized using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) terms. Participants with treatment-emergent toxicities with a frequency of \>=20% in any treatment arm, and participants with at least one toxicity are reported. Taxane subsets (ABI-007 subset and Taxol subset treatment arms) summarize participants with treatment-emergent toxicities defined as any AEs that begin or worsen in severity grade after the start of taxane treatment (cycle 5, week 9) through 30 days after the last dose of taxane (week 20) and were ongoing 3 months after chemotherapy (month 7). Entire regiments (AC --\> ABI-007 and AC --\> Taxol treatment arms) summarize participants with treatment-emergent toxicities defined as any AEs that begin or worsen in severity grade after the start of chemotherapy (cycle 1, week 1) through 30 days after the last dose of chemotherapy (week 20) and were ongoing 3 months after chemotherapy (month 7).
| participants | ABI-007 Subset | AC --> ABI-007 | Taxol Subset | AC --> Taxol |
|---|---|---|---|---|
| At least 1 AE at 3 Months | 65 | 74 | 65 | 77 |
| Neurology: Neuropathy: Sensory | 36 | 50 | 28 | 35 |
| Constitutional Symptoms: Fatigue | 16 | 46 | 10 | 32 |
| Dermatology/Skin: Hair Loss/Alopecia (Scalp+Body) | 2 | 33 | 1 | 17 |
| Endocrine: Hot Flashes/Flushes | 12 | 28 | 5 | 22 |
| Cardiac General: Hypertension | 4 | 18 | 7 | 25 |
| Pain: Arthralgia | 7 | 22 | 8 | 19 |
| Hemorrhage/Bleeding: Nasal | 11 | 19 | 10 | 18 |
| Pain: Other - Extremity | 4 | 15 | 7 | 22 |
| Pain: Myalgia | 10 | 20 | 9 | 16 |
| Dermatology/Skin: Nail Changes | 14 | 22 | 5 | 10 |
| Constitutional Symptoms: Insomnia | 3 | 16 | 5 | 11 |
Percent of the protocol-defined taxane (ABI-007 or Taxol) dose that was actually taken by study participants.
| percentage of protocol-defined taxane | AC --> ABI-007 | AC --> Taxol |
|---|---|---|
| Percent of Protocol Taxane Dose | 91.40 ± 19.218 | 94.40 ± 14.217 |
Counts of participants who * completed the protocol-defined treatment cycles, * had a dose interruption * had a dose reduction * had a dose delay. A dose delay refers to the delay of all interventions in the cycle. Dose modifications are typically caused by clinically significant laboratory abnormalities and /or treatment emergent adverse events/toxicities. Use of pegfilgrastim is included in the summary.
| participants | AC --> ABI-007 | AC --> Taxol |
|---|---|---|
| Completed 4 cycles of Adriamycin/Cytoxan (AC) | 95 | 95 |
| Received pegfilgrastim for 4 cycles during AC | 95 | 94 |
| Completed 4 cycles of taxane | 82 | 84 |
| Completed 18 cycles of bevacizumab | 61 | 61 |
| One or more dose reduction: Adriamycin | 10 | 6 |
| One or more dose reduction: Cytoxan | 9 | 5 |
| One or more dose reduction: Taxane | 12 | 16 |
| One or more dose interruption: Adriamycin | 1 | 0 |
| One or more dose interruption: Cytoxan | 3 | 1 |
| One or more dose interruption: Taxane | 0 | 3 |
| One or more dose interruption: Bevacizumab | 0 | 2 |
| One or more delay in study regimen | 50 | 48 |
| Discontinued pegfilgrastim during AC cycles | 0 | 0 |
| Administered pegfilgrastim during taxane cycles | 23 | 13 |
Myelosuppression represented by neutropenia (low absolute neutrophil counts (ANC)) with severity grades according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE). * Grade 1 = \<lower limit of normal (LLN)-1.5\*10\^9/L * Grade 2 = \<1.5 - 1.0\*10\^9/L * Grade 3 = \<1.0 - 0.5\*10\^9/L * Grade 4 = \<0.5\*10\^9/L Values are reported across all severity grades without assessment of relationship to taxane treatment, and also by relation to taxane treatment as reported by investigators.
| participants | AC --> ABI-007 | AC --> Taxol |
|---|---|---|
| ANC (grades 1-4) | 58 | 43 |
| Taxane-related, grades 1-4 | 11 | 8 |
| Taxane-related, grades 3-4 | 6 | 5 |
Decreased left ventricular ejection fraction (LVEF) is an indication of cardiotoxicity. Change from baseline measurements to the final evaluation are summarized.
| percentage of healthy LVEF | AC --> ABI-007 | AC --> Taxol |
|---|---|---|
| Change From Baseline in Percent Left Ventricular Ejection Fraction (% LVEF) at the Final Evaluation | -1.0 ± 7.40 | -1.0 ± 93.40 |
Summary of the most severe grades using the National Cancer Institute's Common Terminology Criteria for Adverse Events v3.0 (CTCAE) for the following liver and renal function tests. Grade 0 = within normal range for all measurements. Alkaline phosphatase, alanine aminotransferase (ALT), aspartate aminotransferase (AST): * Grade 1 = \> upper limit of normal (ULN) - 2.5\*ULN * Grade 2= \>2.5-5.0\*ULN * Grade 3= \>5.0-20.0\*ULN * Grade 4= \>20.0\*ULN Bilirubin: * Grade 1= \>ULN - 1.5\*ULN * Grade 3= \>3.0 - 10.0\*ULN Creatinine: - Grade 1= \>ULN - 1.5\*ULN
| participants | AC --> ABI-007 | AC --> Taxol |
|---|---|---|
| Alkaline phosphatase, Grade 0 | 69 | 70 |
| Alkaline phosphatase, Grade 1 | 26 | 29 |
| Alkaline phosphatase, Grade 2 | 1 | 0 |
| ALT, Grade 0 | 66 | 75 |
| ALT, Grade 1 | 24 | 23 |
| ALT, Grade 2 | 5 | 1 |
| ALT, Grade 4 | 1 | 0 |
| AST, grade 0 | 74 | 81 |
| AST, grade 1 | 20 | 17 |
| AST, grade 2 | 1 | 1 |
| AST, grade 3 | 1 | 0 |
| Bilirubin, grade 0 | 95 | 98 |
| Bilirubin, grade 1 | 0 | 1 |
| Bilirubin, grade 3 | 1 | 0 |
| Creatinine, grade 0 | 94 | 97 |
| Creatinine, grade 1 | 2 | 2 |
Toxicities are summarized using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) terms. Participants with treatment-emergent toxicities with a frequency of \>=20% in any treatment arm, and participants with at least one toxicity are reported. Taxane subsets (ABI-007 subset and Taxol subset treatment arms) summarize participants with treatment-emergent toxicities defined as any AEs that begin or worsen in severity grade after the start of taxane treatment (cycle 5, week 9) through 30 days after the last dose of taxane (week 20) and were ongoing 6 months after chemotherapy (month 10). Entire regiments (AC --\> ABI-007 and AC --\> Taxol treatment arms) summarize participants with treatment-emergent toxicities defined as any AEs that begin or worsen in severity grade after the start of chemotherapy (cycle 1, week 1) through 30 days after the last dose of chemotherapy (week 20) and were ongoing 6 months after chemotherapy (month 10).
| participants | ABI-007 Subset | AC --> ABI-007 | Taxol Subset | AC --> Taxol |
|---|---|---|---|---|
| At least 1 AE at 6 Months | 49 | 62 | 46 | 65 |
| Neurology: Neuropathy: Sensory | 25 | 42 | 15 | 19 |
| Constitutional Symptoms: Fatigue | 11 | 32 | 4 | 18 |
| Endocrine: Hot Flashes/Flushes | 7 | 23 | 3 | 17 |
| Cardiac General: Hypertension | 4 | 12 | 7 | 18 |
| Pain: Arthralgia | 4 | 17 | 3 | 13 |
| Pain: Myalgia | 8 | 17 | 4 | 8 |
| Pain: Other - Extremity | 1 | 6 | 5 | 14 |
| Dermatology/Skin: Nail Changes | 8 | 13 | 3 | 6 |
Collected over Day 1 - up to week 50 (weeks 1-46 treatment, plus 30 days after last study dose). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AC --> ABI-007 | — | 30/98 (30.6%) | 97/98 (99%) |
| AC --> Taxol | — | 21/99 (21.2%) | 99/99 (100%) |
| Event | AC --> ABI-007 | AC --> Taxol |
|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 7/98 | 5/99 |
| Cardiac failure congestiveCardiac disorders | 0/98 | 4/99 |
| PyrexiaGeneral disorders | 2/98 | 0/99 |
| SepsisInfections and infestations | 2/98 | 0/99 |
| PancytopeniaBlood and lymphatic system disorders | 2/98 | 0/99 |
| Deep vein thrombosisVascular disorders | 2/98 | 0/99 |
| Chest painGeneral disorders | 1/98 | 2/99 |
| SyncopeNervous system disorders | 1/98 | 2/99 |
| Appendicitis perforatedGastrointestinal disorders | 1/98 | 0/99 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/98 | 1/99 |
| Event | AC --> ABI-007 | AC --> Taxol |
|---|---|---|
| FatigueGeneral disorders | 81/98 | 77/99 |
| NauseaGastrointestinal disorders | 77/98 | 79/99 |
| AlopeciaSkin and subcutaneous tissue disorders | 61/98 | 66/99 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 54/98 | 48/99 |
| AnaemiaBlood and lymphatic system disorders | 50/98 | 44/99 |
| ConstipationGastrointestinal disorders | 47/98 | 40/99 |
| MyalgiaMusculoskeletal and connective tissue disorders | 45/98 | 41/99 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 45/98 | 38/99 |
| HeadacheNervous system disorders | 42/98 | 41/99 |
| NeuropathyNervous system disorders | 39/98 | 38/99 |
| Age, Continuous(years) | AC --> ABI-007 | AC --> Taxol | Total |
|---|---|---|---|
| Mean | 51.2 ± 9.21 | 51.2 ± 9.29 | 51.2 ± 9.23 |
| Age, Customized(participants) | AC --> ABI-007 | AC --> Taxol | Total |
|---|---|---|---|
| >=65 years | 9 | 11 | 20 |
| < 65 years | 89 | 88 | 177 |
| Sex: Female, Male(Participants) | AC --> ABI-007 | AC --> Taxol | Total |
|---|---|---|---|
| Female | 98 | 99 | 197 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(participants) | AC --> ABI-007 | AC --> Taxol | Total |
|---|---|---|---|
| Asian | 3 | 2 | 5 |
| White, non-Hispanic, non-Latino | 76 | 72 | 148 |
| White, Hispanic or Latino | 8 | 17 | 25 |
| Black, of African heritage | 10 | 7 | 17 |
| Other | 1 | 1 | 2 |
| Region of Enrollment(participants) | AC --> ABI-007 | AC --> Taxol | Total |
|---|---|---|---|
| United States | 98 | 99 | 197 |
| Weight(kg) | AC --> ABI-007 | AC --> Taxol | Total |
|---|---|---|---|
| Mean | 78.63 ± 19.561 | 78.78 ± 19.595 | 78.71 ± 19.528 |
| Menopausal Status(participants) | AC --> ABI-007 | AC --> Taxol | Total |
|---|---|---|---|
| premenopausal | 50 | 44 | 94 |
| postmenopausal | 48 | 55 | 103 |
| Stage at Primary Diagnosis(participants) | AC --> ABI-007 | AC --> Taxol | Total |
|---|---|---|---|
| I: tumor <=2.0, lymph nodes clear, no metastasis | 10 | 7 | 17 |
| IIa: tumor <=2.0 cm, regional lymph node | 28 | 35 | 63 |
| IIb: tumor >2.0<5.0cm, regional lymph nodes | 32 | 24 | 56 |
| IIIa: tumor may be >5.0 cm, regional lymph nodes | 22 | 23 | 45 |
| IIIb: tumor extending to chest wall or skin | 0 | 0 | 0 |
| IIIc: tumor with extensive lymph node involvement | 6 | 9 | 15 |
| IV: distant metastasis | 0 | 0 | 0 |
| unknown | 0 | 1 | 1 |
4 further baseline measures are reported on the registry.
Ran from Aug 2006 to primary completion in Mar 2007, 7 months.
Results were first posted in Jul 2013, 6 years 4 months after primary completion.
Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 7 months is below that.
Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Albumin-Bound Paclitaxel · Paclitaxel